Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a disorder in which the kidneys retain water despite conditions that would normally permit its excretion. The resulting excess of water relative to body sodium produces hyponatremia, usually with reduced plasma osmolality and urine that remains inappropriately concentrated. Patients generally appear clinically euvolemic: they do not have the obvious fluid depletion of dehydration or the peripheral swelling associated with major fluid-overload disorders.
SIADH is an important cause of hyponatremia in hospitalized patients and can accompany pulmonary disease, neurological illness, malignancy, medication exposure, and postoperative stress. Its consequences range from subtle disturbances of attention and gait to seizures and life-threatening brain swelling. Both the fall in sodium concentration and its subsequent correction can cause neurological injury, making the time course of the disorder central to its interpretation.
The term syndrome of inappropriate antidiuresis (SIAD) is increasingly used because the defining abnormality is impaired water excretion, not necessarily demonstrably excessive hormone secretion. Diagnosis depends on a pattern of blood and urine findings, together with exclusion of conditions that produce a similar pattern. Management distinguishes urgent treatment of neurological complications from longer-term control of water balance and identification of the underlying cause.
Definition and physiological boundaries
The central abnormality in SIADH is a failure to excrete sufficiently dilute urine when plasma is already hypotonic. Antidiuretic hormone, more commonly called arginine vasopressin, normally conserves water when circulating fluids become concentrated or when effective circulating blood volume falls. In SIADH, antidiuretic activity persists without an appropriate osmotic or circulatory stimulus. Consequently, ordinary water intake can exceed the kidney’s capacity to eliminate electrolyte-free water.
Hyponatremia is conventionally defined as a serum sodium concentration below . This measurement describes a concentration, not total body sodium content. In SIADH, the initial disturbance is usually excess retained water rather than primary sodium depletion. Mild expansion of extracellular fluid subsequently promotes urinary sodium excretion, so some sodium loss can contribute to the established biochemical pattern. Nevertheless, describing the disorder simply as “salt deficiency” misrepresents its principal mechanism.
The distinction between osmolality and tonicity is important. Osmolality counts dissolved particles per kilogram of water; tonicity describes the effects of solutes that sustain water movement across cell membranes. Urea contributes to measured plasma osmolality but generally has little sustained effect on tonicity because it crosses many cell membranes. In contrast, extracellular sodium salts are major determinants of tonicity. SIADH ordinarily produces hypotonic hyponatremia, whereas marked hyperglycemia can lower measured sodium while increasing extracellular tonicity.
Clinical euvolemia does not imply perfectly normal total body water. A modest increase in water content may be present, but compensatory sodium excretion and other adaptations limit overt extracellular expansion. Peripheral edema, ascites, or clear evidence of circulatory depletion therefore suggests another explanation or an additional disorder. Physical assessment of volume status is imperfect, especially in older or acutely ill patients, so the classification cannot rest on appearance alone.
SIADH is a syndrome rather than a single disease. Different mechanisms can produce the same laboratory phenotype, and more than one mechanism may operate in one patient. A person with pulmonary infection, for example, may simultaneously experience nausea, receive a medication that enhances antidiuresis, and consume little dietary solute. The label identifies a physiological pattern; it does not by itself establish the underlying cause.
Vasopressin signaling and impaired water excretion
Vasopressin is synthesized principally in the supraoptic and paraventricular nuclei of the hypothalamus and transported to the posterior pituitary for release. Osmoregulatory pathways normally suppress its secretion when plasma becomes dilute. Separate circulatory pathways stimulate release during reduced effective arterial blood volume. Pain, nausea, stress, and several drugs can also stimulate secretion, sometimes overriding the osmotic signal that would otherwise suppress it.
In the kidney, vasopressin binds to V2 receptors on the basolateral surface of collecting-duct principal cells. Receptor activation stimulates cyclic adenosine monophosphate signaling and promotes insertion of aquaporin-2 water channels into the apical membrane. Water then enters from the tubular lumen and exits toward the interstitium through basolateral water channels. The medullary osmotic gradient provides the driving force for this reabsorption. Persistent signaling therefore permits concentrated urine to be produced even while plasma sodium is falling.
The importance of solute intake follows from a simple relationship:
where is the maximum urine volume achievable under the prevailing conditions. For example, excretion of 600 milliosmoles per day at a urine osmolality of permits only about one liter of urine. If dietary protein and salt intake fall, the daily osmole load falls as well, further reducing water-excretory capacity. This explains why water intake that is harmless in normal physiology can produce progressive hyponatremia during persistent antidiuresis.
Early water retention causes slight extracellular expansion. Suppression of the renin–angiotensin–aldosterone system and increased natriuretic activity then promote sodium excretion. During prolonged vasopressin exposure, reduced collecting-duct responsiveness can also limit further retention, a phenomenon often called escape from antidiuresis. These responses help explain why SIADH usually does not cause continuously progressive fluid accumulation or conspicuous edema.
Not every case requires excessive circulating vasopressin. Activating variants in the gene encoding the V2 receptor can cause nephrogenic syndrome of inappropriate antidiuresis, first described in 2005. In this rare inherited condition, receptor activity persists despite low or undetectable vasopressin. Some acquired cases also lack a straightforward relationship between measured hormone concentration and the severity of antidiuresis. These observations support the broader terminology “inappropriate antidiuresis.”
Underlying diseases, medications, and transient triggers
Malignancy is a well-established cause of SIADH. The classical association is small-cell lung cancer, whose neuroendocrine tumor cells may synthesize and release vasopressin independently of normal hypothalamic regulation. Hyponatremia may precede recognition of the tumor, occur during established disease, or recur with tumor progression. Not all hyponatremia in a patient with cancer is paraneoplastic, however: poor intake, vomiting, adrenal dysfunction, renal injury, and treatment-related effects can produce alternative or additional mechanisms.
Disorders of the central nervous system can disturb vasopressin regulation. Recognized settings include meningitis, encephalitis, traumatic brain injury, intracranial tumors, and hemorrhage, including subarachnoid hemorrhage. Neurological illness also introduces diagnostic complexity because sodium depletion, glucocorticoid deficiency, intravenous fluid administration, and medications may coexist. The presence of a brain lesion therefore does not automatically establish SIADH as the cause of a low sodium concentration.
Pulmonary disorders are another major group of associations. Pneumonia, tuberculosis, and acute respiratory failure can be accompanied by inappropriate antidiuresis. The mechanisms may include hypoxemia, stress signaling, inflammatory effects, and altered circulatory inputs rather than direct hormone production by lung tissue. Positive-pressure mechanical ventilation can also influence circulatory signals relevant to vasopressin release. The relative contributions vary with the clinical setting.
Drug-associated cases involve several mechanisms: increased vasopressin release, enhanced renal responsiveness to the hormone, or direct stimulation of antidiuretic pathways. Commonly implicated groups include selective serotonin reuptake inhibitors, some antipsychotics, and antiseizure drugs such as carbamazepine and oxcarbazepine. Fluoxetine is one example of an antidepressant associated with hyponatremia. Cyclophosphamide, vincristine, opioids, and some other medicines may also contribute. Nonsteroidal anti-inflammatory drugs can reduce renal prostaglandin-mediated opposition to vasopressin, amplifying water retention.
Transient antidiuresis frequently follows surgery, particularly when postoperative pain, nausea, stress, and hypotonic fluid intake occur together. Nausea is a particularly potent nonosmotic stimulus for vasopressin secretion. These situations require careful terminology: transient hormone release may reflect a recognizable stress response, even though continued water retention becomes inappropriate for the prevailing plasma tonicity. In older adults, apparently unexplained SIADH may remain after investigation, but the designation “idiopathic” depends on the adequacy of medication review and exclusion of other disorders.
Clinical manifestations and cerebral adaptation
The manifestations of SIADH arise mainly from hypotonic hyponatremia rather than from vasopressin excess itself. Water moves into cells when extracellular tonicity falls. Within the rigid skull, enlargement of brain cells can raise intracranial pressure and impair neurological function. The clinical severity therefore depends not only on the sodium concentration but also on how quickly it changes, the patient’s previous sodium level, and the presence of other neurological disease.
Early symptoms may include nausea, malaise, headache, reduced concentration, and lethargy. More severe manifestations include confusion, vomiting, reduced consciousness, and seizures. Profound acute hypotonicity can cause respiratory arrest and brain herniation. These symptoms are not specific to SIADH: infection, medications, intracranial pathology, and metabolic disturbances may produce similar findings, so attributing all neurological abnormalities to the sodium result can be misleading.
The brain adapts to sustained hypotonicity by reducing intracellular solute content. Electrolytes are lost relatively early, followed by organic osmolytes that help regulate cell volume. Over approximately 48 hours and beyond, this adaptation reduces swelling and explains why some patients with chronic, marked hyponatremia have less dramatic symptoms than patients with a more modest but abrupt fall. The same adaptation creates vulnerability during correction, because brain cells cannot immediately restore their lost osmolytes.
Acute hyponatremia is conventionally defined as developing within 48 hours, whereas chronic hyponatremia has persisted for at least that long. When the duration is unknown, clinical correction strategies generally account for the possibility of chronic adaptation. These categories are useful but not absolute biological boundaries: the rate and extent of adaptation vary, and earlier unmeasured fluctuations may complicate the history.
Chronic mild hyponatremia was historically regarded as largely asymptomatic. Observational studies and small physiological investigations have associated it with impaired attention, gait disturbance, falls, and fractures. It is also associated with lower bone density in some populations. These findings do not establish that hyponatremia alone explains every adverse outcome, since age, medications, cancer, and other illnesses are important confounders. Nevertheless, they show why a persistent sodium concentration just below the reference range is not necessarily biologically inert.
Diagnostic criteria and interpretation of laboratory findings
SIADH is diagnosed from a compatible biochemical pattern after alternative explanations have been excluded. The usual core findings are hypotonic hyponatremia, urine that is not maximally dilute, clinical euvolemia, urinary sodium excretion that is not appropriately suppressed, and adequate adrenal, thyroid, and renal function. Recent diuretic exposure can make the standard criteria difficult to apply. No single blood test establishes the diagnosis independently of this context.
Measured plasma osmolality is commonly below . A urine osmolality above indicates that water excretion is not maximally dilute, although it does not by itself identify the reason. Urinary sodium is often above when dietary sodium intake is adequate and there is no major confounding influence. A lower urine sodium does not exclude SIADH in a person with very low salt intake, while a higher value can occur with diuretics, adrenal insufficiency, or renal salt loss.
Plasma and urine specimens obtained close together are especially informative because both can change quickly after fluids, medication withdrawal, or resolution of nausea. Urine sodium concentration also varies with recent intake and urine volume. Interpretation is therefore physiological rather than purely threshold-based. The medical history, medication timeline, fluid administration record, and physical examination help determine whether a laboratory pattern represents persistent inappropriate antidiuresis or a transient response to another disturbance.
Low serum uric acid and low urea concentrations can support the diagnosis. Increased fractional excretion of urate is another supportive finding, reflecting altered proximal tubular handling during the mildly expanded state. These measurements are not specific enough to replace assessment of adrenal function and other exclusions. In selected patients taking diuretics, fractional urate excretion may provide additional information, but its usefulness differs among diuretic-associated disorders.
Direct vasopressin measurement is not routinely required. The hormone is technically difficult to measure, and its concentration must be interpreted against plasma osmolality, circulatory status, and recent stress. Copeptin, a more stable peptide released with vasopressin, has research and selected diagnostic applications but substantial overlap occurs among causes of hyponatremia. Imaging is directed by the suspected cause rather than by the sodium value alone; chest imaging or magnetic resonance imaging of the brain may be relevant when clinical findings indicate pulmonary or neurological disease.
Distinguishing SIADH from other forms of hyponatremia
The first step in the differential diagnosis is separating true hypotonic hyponatremia from other low-sodium states. Severe hyperglycemia draws water from cells into extracellular fluid, lowering sodium concentration despite increased tonicity. Pseudohyponatremia is a measurement artifact associated with marked hyperlipidemia or hyperproteinemia when sodium is measured by certain indirect methods. Direct ion-selective electrode measurements, such as those used by many blood-gas analyzers, are not affected by this electrolyte-exclusion artifact in the same way.
Volume depletion produces appropriately increased vasopressin secretion. Gastrointestinal losses, renal sodium losses, and diuretic use can therefore produce concentrated urine and hyponatremia without SIADH. Conversely, heart failure and cirrhosis may involve increased total body fluid but reduced effective arterial circulation. The resulting antidiuresis is driven by circulatory physiology. Edema, ascites, cardiac findings, and the broader clinical context help distinguish these disorders from euvolemic inappropriate antidiuresis.
Adrenal insufficiency is a particularly important mimic. Cortisol deficiency increases vasopressin activity and impairs water excretion; secondary adrenal insufficiency may present with apparent euvolemia and normal potassium, closely resembling SIADH. Primary adrenal failure can additionally cause mineralocorticoid deficiency, sodium wasting, and hyperkalemia. Severe hypothyroidism, especially in advanced systemic illness, can also impair water clearance. Mild thyroid dysfunction alone is generally not an adequate explanation for substantial hyponatremia.
Primary polydipsia and low-solute intake limit water balance in different ways. In primary polydipsia, water intake exceeds excretory capacity, often with very dilute urine. Low dietary protein and salt reduce the osmoles available for urinary excretion, allowing hyponatremia to develop at lower fluid intakes. Urine osmolality may rise if nausea or another vasopressin stimulus coexists. A reset osmostat is another distinct physiological pattern in which water regulation operates around a lower plasma osmolality; sodium may remain stably reduced while the capacity to dilute urine is preserved under appropriate conditions.
Cerebral or renal salt wasting can resemble SIADH after neurological injury because both may produce hyponatremia, concentrated urine, and urinary sodium loss. Salt wasting implies net sodium depletion and reduced extracellular volume, whereas SIADH is primarily a disorder of water retention. Reliable distinction can be difficult, and reported frequencies depend heavily on diagnostic definitions. Isotonic saline may improve sodium in true volume depletion by removing the circulatory stimulus to vasopressin, but it may be ineffective or worsen hyponatremia in SIADH if concentrated urine eliminates the infused sodium while retaining a substantial proportion of the water.
Severe symptoms, correction limits, and neurological complications
Management of severe symptomatic hyponatremia initially addresses the threat from cerebral swelling, before the precise cause has necessarily been established. Hospital protocols use hypertonic saline to produce a controlled early rise in sodium, with repeated clinical assessment and frequent laboratory measurement. The immediate objective is partial reversal of dangerous hypotonicity, not rapid restoration of a normal sodium concentration. This distinction is central because excessive correction can create a second neurological emergency.
European and North American guidance commonly describes an initial increase of approximately – as sufficient to reduce acute cerebral edema substantially. The exact protocol, including whether hypertonic saline is given as intermittent boluses or a controlled infusion, varies by guideline and clinical setting. The presence of seizures or markedly impaired consciousness matters more for initial urgency than a sodium threshold considered in isolation. Published correction targets are professional treatment frameworks, not stand-alone instructions detached from monitoring.
The principal delayed complication is osmotic demyelination syndrome. After adaptation to chronic hypotonicity, a rapid increase in extracellular tonicity can injure oligodendrocytes and disrupt myelin, particularly in the pons and sometimes in extrapontine structures. Neurological deterioration may occur several days after an initial improvement. Manifestations can include dysarthria, difficulty swallowing, movement abnormalities, weakness, and severe disturbances of consciousness. MRI findings may lag behind symptoms.
Correction ceilings differ slightly among guidelines. European guidance has used a limit of in the first 24 hours and during each subsequent 24-hour period. More conservative limits, commonly no more than in any 24 hours, are emphasized for patients at high risk. Established risk factors include extremely low initial sodium, alcohol use disorder, malnutrition, hypokalemia, and advanced liver disease. These are upper safety boundaries rather than goals, and osmotic demyelination has occasionally occurred despite correction within conventional limits.
Overcorrection often results from an abrupt water diuresis rather than simply excessive saline administration. When nausea resolves, a causative drug is stopped, or cortisol deficiency is treated, vasopressin activity may fall and large volumes of dilute urine may appear. Potassium replacement can also increase serum sodium and must be considered in the correction trajectory. Closely monitored clinical protocols may use desmopressin to limit water losses and electrolyte-free fluid to reverse an excessive rise. This illustrates why urine output and repeated sodium measurements are as important as the prescribed infusion.
Longer-term control of inappropriate antidiuresis
Longer-term management separates treatment of the underlying cause from control of the water-balance disturbance. Resolution of pneumonia, successful treatment of a vasopressin-producing tumor, or withdrawal of a causative medication may restore normal regulation. Some causes are transient, whereas neurological disease, malignancy, or unexplained persistent antidiuresis can require extended monitoring. Changes in treatment of the underlying illness may themselves alter water excretion abruptly.
Fluid restriction is widely used for stable chronic SIADH because it reduces water intake below the amount that can be excreted. Its effect depends on urine concentration, dietary solute intake, kidney function, and adherence. Highly concentrated urine and low urine volume predict a limited response. The combined urinary sodium and potassium concentrations, compared with plasma sodium, can help estimate whether electrolyte-free water is being excreted. Persistent thirst, intravenous fluids, and water contained in food or medication preparations can complicate implementation.
Increasing osmole excretion offers a different mechanism. Oral urea raises urinary osmole output, allowing more water to be eliminated despite continued antidiuresis. Its use varies substantially between countries and clinical services; palatability and the limited size of controlled evidence are important practical issues. Salt administration is sometimes combined with a loop diuretic, which reduces the kidney’s concentrating capacity. This approach can produce hypokalemia, renal dysfunction, or other adverse effects, and randomized evidence has not established a consistent advantage over fluid restriction alone.
V2-receptor antagonists, often called vaptans, block vasopressin-mediated water reabsorption and produce aquaresis: increased excretion of water without a proportionate increase in electrolytes. Tolvaptan is an oral selective V2 antagonist; conivaptan, used intravenously in some settings, blocks V1a and V2 receptors. These drugs can raise sodium effectively, but responses may be brisk and unpredictable, particularly with very low starting sodium. Thirst, excessive correction, cost, regulatory restrictions, and concerns about liver injury with prolonged tolvaptan exposure affect their use. Guideline positions differ, especially for profound hyponatremia and routine use in chronic SIADH.
Demeclocycline has historically been used because it reduces renal responsiveness to vasopressin, but delayed action, unpredictable effects, and nephrotoxicity limit its role. Lithium has similar historical relevance but an unfavorable safety profile for this purpose. Across treatment options, biochemical improvement is not equivalent to proven improvement in survival, cognition, or fracture risk. Choice among therapies therefore involves evidence about sodium correction, the underlying disease, treatment burden, and the ability to monitor safely.
Historical development, epidemiology, and clinical evidence
The classical clinical description appeared in 1957, when William Schwartz, William Bennett, Saul Curelop, and Frederic Bartter reported two patients with bronchogenic carcinoma, persistent hyponatremia, and renal sodium loss. They proposed inappropriate secretion of antidiuretic hormone as the explanation. This work helped establish a framework in which water retention, rather than an isolated defect in sodium conservation, could account for the biochemical findings. The eponym Schwartz–Bartter syndrome arose from this early literature.
Subsequent physiological investigations showed that SIADH was not a uniform secretory disorder. Different patients displayed different relationships between plasma osmolality and circulating vasopressin, including relatively unregulated secretion and regulation around an abnormally low osmotic threshold. Identification of constitutively active renal V2 receptors in 2005 further separated inappropriate antidiuresis from excessive hormone secretion. Modern terminology consequently emphasizes the final physiological effect while preserving SIADH as a familiar clinical name.
The epidemiology of SIADH is difficult to quantify precisely. Hyponatremia is common in hospitalized populations, but studies differ in the sodium threshold used, the timing of measurement, and whether all diagnostic exclusions were completed. Administrative diagnostic codes may not reliably distinguish SIADH from other forms of euvolemic hyponatremia. Apparent frequency also depends on case mix: oncology, pulmonary medicine, and neurological services encounter different causal patterns. Older patients are particularly likely to have several simultaneous contributors rather than a single cleanly defined mechanism.
Randomized studies have clarified some treatment effects without resolving all clinically important questions. The SALT-1 and SALT-2 trials, published in 2006, showed that tolvaptan increased sodium in patients with euvolemic or hypervolemic hyponatremia, including a subgroup with SIADH. Their populations were not restricted to SIADH, and biochemical efficacy did not establish a survival benefit. A later randomized trial of fluid restriction in chronic SIADH found a modest sodium improvement, with substantial numbers of patients remaining hyponatremic. Trials of additional salt and loop-diuretic treatment have also demonstrated the importance of measuring adverse effects rather than sodium alone.
Persistent uncertainties concern which patients with mild chronic hyponatremia benefit from active correction, how best to compare second-line therapies, and whether correction improves falls, cognition, fractures, or long-term survival. Associations between hyponatremia and adverse outcomes are strong, but underlying illness can both lower sodium and worsen prognosis. Research increasingly distinguishes laboratory normalization from patient-centered outcomes and examines whether treatment benefits differ according to cause, duration, symptom burden, and risk of overcorrection.